Posted by Michael Wonder on 01 Sep 2023
Department publishes revised agenda for November 2023 PBAC meeting
1 September 2023 - The initial agenda for the November 2023 PBAC meeting has been updated.
There are many additions/changes; the major ones are as follows:
- Cytosine arabinoside with daunorubicin (nanoparticle, liposomal) (Vyxeos) - new combination product (resubmission)
- Secukinumab (Cosentyx) - new indication (resubmission)
- Mavacamten (Camyzos) - new medicine (resubmission)
- Sacituzumab govitecan (Trodelvy) - new indication (resubmission)
- Varicella zoster virus vaccine (adjuvanted) (Shingrix) - new vaccine (resubmission)
- Dupilumab (Dupixent), upadacitinib monohydrate (Rinvoq) - review of cost-effectiveness when used for the treatment of patients with severe atopic dermatitis
